Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings

Risk and Timing of Neutropenic Events in Adult Cancer Patients Receiving Chemotherapy: The Results of a Prospective Nationwide Study of Oncology Practice

(2017) Jeffrey Crawford et al.   Journal of the National Comprehensive Cancer Network

Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline

(2013) Christopher R. Flowers et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk and Healthcare Costs of Chemotherapy-Induced Neutropenic Complications in Women with Metastatic Breast Cancer

(2012) Derek Weycker et al.   CHEMOTHERAPY

Colony-Stimulating Factor Use and Impact on Febrile Neutropenia Among Patients with Newly Diagnosed Breast, Colorectal, or Non-Small Cell Lung Cancer Who Were Receiving Chemotherapy

(2012) Jeannine S. McCune et al.   PHARMACOTHERAPY

Single-Agent, Broad-Spectrum Fluoroquinolones for the Outpatient Treatment of Low-Risk Febrile Neutropenia

(2011) Maryann R Cooper et al.   ANNALS OF PHARMACOTHERAPY

Executive Summary: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America

(2011) Alison G. Freifeld et al.   CLINICAL INFECTIOUS DISEASES

Safety of Early Discharge for Low-Risk Patients With Febrile Neutropenia: A Multicenter Randomized Controlled Trial

(2011) James A. Talcott et al.   JOURNAL OF CLINICAL ONCOLOGY

No Place Like Home? Outpatient Management of Patients With Febrile Neutropenia and Low Risk

(2011) Alison G. Freifeld et al.   JOURNAL OF CLINICAL ONCOLOGY

Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: A retrospective study

(2011) M. BLANE SCHILLING et al.   Experimental and Therapeutic Medicine

Risk of mortality in patients with cancer who experience febrile neutropenia

(2010) Gary H. Lyman et al.   CANCER

Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma

(2010) Hans Wildiers et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the united states

(2009) Gary H. Lyman et al.   CLINICAL THERAPEUTICS

Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy

(2008) R. Pettengell et al.   ANNALS OF HEMATOLOGY

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study

(2008) Ruth Pettengell et al.   BRITISH JOURNAL OF HAEMATOLOGY

Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis

(2008) G. von Minckwitz et al.   EUROPEAN JOURNAL OF CANCER

Outcomes and Cost of Outpatient or Inpatient Management of 712 Patients With Febrile Neutropenia

(2008) Linda S. Elting et al.   JOURNAL OF CLINICAL ONCOLOGY

Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study

(2008) Ruth Pettengell et al.   SUPPORTIVE CARE IN CANCER

Cost-Effectiveness of Primary versus Secondary Prophylaxis with Pegfilgrastim in Women with Early-Stage Breast Cancer Receiving Chemotherapy

(2008) Scott D. Ramsey et al.   VALUE IN HEALTH